BVF as of March 31, 2013
Portfolio Holdings for BVF
BVF holds 31 positions in its portfolio as reported in the March 2013 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Ligand Pharmaceuticals In (LGND) | 16.1 | $97M | 3.6M | 26.65 | |
| Ironwood Pharmaceuticals (IRWD) | 16.0 | $96M | 5.3M | 18.28 | |
| Chemocentryx | 11.6 | $70M | 5.0M | 13.82 | |
| Rigel Pharmaceuticals | 9.8 | $59M | 8.7M | 6.79 | |
| Array BioPharma | 9.4 | $56M | 11M | 4.92 | |
| Amgen (AMGN) | 8.6 | $51M | 500k | 102.51 | |
| Targacept | 4.4 | $26M | 6.2M | 4.28 | |
| Qlt | 4.0 | $24M | 2.7M | 8.84 | |
| Exelixis Inc cnv | 3.1 | $18M | 18M | 1.00 | |
| Regulus Therapeutics | 2.5 | $15M | 1.9M | 7.75 | |
| Cytokinetics | 2.0 | $12M | 10M | 1.14 | |
| Pain Therapeutics | 1.9 | $11M | 3.3M | 3.43 | |
| Exelixis (EXEL) | 1.7 | $10M | 2.2M | 4.62 | |
| ISIS Pharmaceuticals | 1.6 | $9.8M | 577k | 16.94 | |
| Oncothyreon | 1.2 | $7.5M | 3.6M | 2.08 | |
| ArQule | 1.1 | $6.8M | 2.6M | 2.59 | |
| Endocyte | 1.0 | $6.1M | 492k | 12.45 | |
| Vanda Pharmaceuticals (VNDA) | 0.7 | $4.5M | 1.1M | 3.92 | |
| ACADIA Pharmaceuticals (ACAD) | 0.5 | $3.1M | 393k | 7.94 | |
| Palatin Technologies | 0.5 | $3.1M | 5.2M | 0.60 | |
| Anthera Pharmaceuticals | 0.5 | $3.0M | 4.5M | 0.66 | |
| AVANIR Pharmaceuticals | 0.4 | $2.1M | 782k | 2.75 | |
| Capstone Therapeutics | 0.3 | $1.8M | 7.8M | 0.23 | |
| Genvec | 0.3 | $1.7M | 1.1M | 1.51 | |
| DURECT Corporation | 0.2 | $1.5M | 1.1M | 1.33 | |
| Flamel Technologies | 0.2 | $957k | 217k | 4.42 | |
| Astex Pharmaceuticals | 0.1 | $828k | 186k | 4.46 | |
| Transcept Pharmaceuticals | 0.1 | $719k | 150k | 4.79 | |
| Cadus Corporation | 0.1 | $380k | 269k | 1.41 | |
| Myrexis (MYRX) | 0.0 | $167k | 1.7M | 0.10 | |
| NeurogesX | 0.0 | $72k | 1.2M | 0.06 |
